MOTS-C 40MG
METABOLIC RESEARCH
GLP3-RTA 40mg
Metabolic Research, Research Peptide Pens
One pre-filled 40mg GLP3-RTA research pen, prepared after your order with batch-linked documentation.
£179.00Free UK tracked delivery
Compare GLP3-RTA options20mg and 40mg→
- Made fresh to order
- Batch documentation pending
- UK tracked delivery
- Order by 1pm on working days for same-day dispatch
- Results published when verified
Research Use Only
GLP3-RTA 40mg is a synthetic single-chain peptide that acts as an agonist at three receptors: GIP, GLP-1 and glucagon. It is supplied in one pre-filled research pen. Every GLP3-RTA pen is prepared to order in the UK and shipped cold chain by tracked delivery.
Because it engages three receptors at once, GLP3-RTA is used to study how incretin and glucagon signalling interact in metabolic models. It is also available as GLP3-RTA 20mg, and our research compound guide covers related metabolic peptides such as cagrilintide.
How GLP3-RTA is studied
GLP3-RTA is a 39-amino-acid peptide carrying a fatty diacid side chain, which binds albumin and extends its half-life. In cell assays it activated the human GIP, GLP-1 and glucagon receptors; it was more potent than native GIP at the GIP receptor and less potent than the native hormones at the GLP-1 and glucagon receptors. In mice fed a high-fat diet it was studied for its effects on food intake, energy expenditure and body weight, and the glucagon-receptor component was linked to higher energy expenditure.
5 key research areas
- Triple receptor pharmacology. Cell-based assays measured its activity at the human GIP, GLP-1 and glucagon receptors.
- Glucose and insulin signalling. It has been examined for effects on insulin secretion and glucose handling in rodent models and early clinical pharmacology studies.
- Energy expenditure. Mouse studies linked its glucagon-receptor activity to increased energy expenditure.
- Food intake and body weight in rodent models. Mice fed a high-fat diet were used to examine food intake and changes in body weight.
- Pharmacokinetics. Fatty-acid acylation and albumin binding were examined as the basis for its long half-life.
Selected published research
Peer-reviewed studies on the compound, with PubMed IDs:
- Coskun T, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. PMID 35985340
- Urva S, et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. PMID 36354040
- Jastreboff AM, et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity – a phase 2 trial. New England Journal of Medicine. PMID 37366315
- Rosenstock J, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. PMID 37385280
These references describe laboratory, animal and clinical research on this compound, studied elsewhere as an investigational compound. They are cited as scientific background only and do not make this research material suitable for human use.
What arrives
40mg pen
One pre-filled Apexion research pen
One pre-filled Apexion research pen
Single compound
GLP3-RTA, triple GIP, GLP-1 and glucagon receptor agonist
GLP3-RTA, triple GIP, GLP-1 and glucagon receptor agonist
Protected packaging
Discreet and tamper-evident
Discreet and tamper-evident
Batch traceability
Batch number on every pen; independent testing in progress
Batch number on every pen; independent testing in progress
Preparation and UK dispatch
- Made fresh to order after checkout
- Prepared and quality checked before dispatch
- Tracked Royal Mail delivery across the UK
- UK-based product and documentation support
Simple, secure checkout
Pay by Bank is the preferred option
Card payments are temporarily unavailable.
Card payments are temporarily unavailable.
Independent testing is in progress; results will be published only when verified evidence is available.
Research use only. GLP3-RTA is supplied for in-vitro laboratory research by qualified researchers. It is not a medicine, is not licensed by the MHRA, and is not intended for human or veterinary use, diagnosis or treatment.
| Content | 40 mg GLP3-RTA, one pre-filled research pen |
|---|---|
| Purity | 99.651%, as stated in the independent laboratory documentation for the source material |
| CAS | 2381089-83-2 |
| Molecular formula | C221H342N46O68 |
| Molecular weight | ~4731.3 g/mol |
| Form | Pre-filled research pen |
| Origin | UK-stocked, tracked Royal Mail dispatch |
| Intended use | Laboratory research only. Not for human consumption. |
APEXION BIOLABS
Quality & Verification
Batch Verification Record
Independent analytical testing documentation for GLP3-RTA 40mg.
Verification statusIndependent analytical testing verified (source material)
Product & Record
| Product | GLP3-RTA 40mg |
|---|---|
| Apexion verification ID | AX-QV-RTA-001 |
| Analytical laboratory | Janoshik Analytical |
| Documentation status | Supporting laboratory documentation available |
| Finished pen batch testing | In progress. Results will be published here once verified. |
Documented Analytical Information
| Material tested | GLP3-RTA (retatrutide), 40mg source material sample |
|---|---|
| Purity specification | 99.651% - purity result stated in the supporting documentation |
| Independent analysis | Analytical testing performed by Janoshik Analytical (analysis completed 9 July 2026) |
Verification Statement
Apexion BioLabs has reviewed and recorded the supporting independent analytical documentation for this product. Laboratory analysis was performed by Janoshik Analytical. The original laboratory documentation is retained within Apexion quality records and is not altered or re-issued as an Apexion laboratory report.
Documentation Transparency
This record presents the analytical information supported by the corresponding laboratory documentation. Commercial supply-chain information is kept private, while the independent laboratory and documented analytical scope are presented clearly for customer verification.
The material identified in the supporting laboratory documentation is GLP3-RTA (retatrutide) source material. Only analytical tests documented by the laboratory are represented on this record.
Independent lab analysisSupporting documentationApexion verification record
Apexion BioLabs – Batch Verification RecordAX-QV-RTA-001
| Documentation status | Independent source-material analysis available (Janoshik Analytical); finished-pen batch testing in progress |
|---|---|
| Test method | HPLC (purity and identity) |
| Analysis | Independent third-party laboratory, plus in-house QC on every pen |
| Verification | Batch number on every pen; COA linked by QR once published |
Storage conditions
- Shipped cold chain to keep the pen cool in transit
- Long-term: −20 °C in a temperature-controlled environment
- Short-term: keep cool and stable (2–8 °C) and away from direct light
- Keep the pen sealed when not in use
- Avoid repeated temperature changes (freeze–thaw cycles)
Handling guidance
- Check that the packaging and tamper seal are intact on arrival
- Handle as little as possible, using standard laboratory practice
- Record the batch number for traceability
- Follow any batch-specific guidance supplied with your order
What is GLP3-RTA?
GLP3-RTA is a synthetic peptide that acts on three receptors: GIP, GLP-1 and glucagon. It has been studied in cell assays, rodent metabolic models and clinical pharmacology research. Apexion supplies it for laboratory research only.
What is the difference between GLP3-RTA 20mg and 40mg?
Both pens contain the same compound. The 20mg pen holds 20 mg and the 40mg pen holds 40 mg; preparation, packaging and documentation are the same for both.
How does GLP3-RTA differ from cagrilintide?
GLP3-RTA acts on the GIP, GLP-1 and glucagon receptors. Cagrilintide is a long-acting amylin analogue that acts on amylin and calcitonin receptors. They are used to study different signalling pathways, and both are supplied for research use only.
Is GLP3-RTA independently tested?
Every GLP3-RTA pen is made fresh after your order is placed, so each one is prepared and quality checked to order rather than taken from old stock. Independent third-party testing of GLP3-RTA is under way, and the batch Certificate of Analysis will be published as soon as the results are verified. Each pen carries a batch number, so its documentation can be traced.
Can GLP3-RTA be used in humans or animals?
No. GLP3-RTA is not a medicine and is not licensed by the MHRA. It is supplied strictly for in-vitro laboratory research, and is not for human or veterinary use, diagnosis or treatment.
How should GLP3-RTA be stored?
GLP3-RTA is shipped cold chain. On arrival, keep the pen sealed and store it at −20 °C for long-term storage, away from heat and direct light. Handle it as little as possible and follow any batch-specific guidance supplied with your order.
Upsell
Frequently bought together
Bundle price
£259.00
£289.00
Save £30.00
Compare
Compare with GLP3-RTA 20mg
| This product GLP3-RTA 40mg | GLP3-RTA 20mg | |
|---|---|---|
| Contents | 40 mg GLP3-RTA, one pre-filled research pen | 20 mg GLP3-RTA, one pre-filled research pen |
| Format | Pre-filled research pen | Pre-filled research pen |
| Price | £179.00 | £129.00 |
| Price per mg | £4.48 | £6.45 |
| Independent testing | Independent source-material analysis available (Janoshik Analytical); finished-pen batch testing in progress | Independent testing in progress |
| View GLP3-RTA 20mg |
Price per mg is the price divided by the total labelled contents. For laboratory research use only.
Cross-sell
